[Resistance to activated protein C and pregnancy: thromboprophylaxis with low molecular weight heparin].
OBJECTIVE
The utilization, during pregnancy, of low molecular weight heparin (enoxaparine) for obstetric thromboprophylaxis for patients with activated protein C resistance, following Factor V Leiden mutation.


METHODS
Prospective study enrolling 10 pregnant patients heterozygote or homozygote for Factor V Leiden mutation. They all had familial or personal history of severe thrombotic disease and received 40 mg per day of enoxaparine.


RESULTS
No thrombosis or hemorrhage were recorded during pregnancies or deliveries. All the infants were doing well. After birth, low molecular, weight heparin were continued between 6 to 12 weeks accordingly allelic status and history. We reviewed the literature on this subject.


CONCLUSIONS
This series confirmed the efficacy, safety and tolerance of low molecular weight heparins which will probably become the next gold standard for obstetric thromboprophylaxis.
Barjot
P
P
Service de Gynécologie-Obstétrique, CHU de Caen.
Beucher
G
G
Le Querrec
A
A
Derlon-Borel
A
A
Herlicoviez
M
M
D020016:Activated Protein C Resistance / Q000188:drug therapy* / Q000235:genetics; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D017984:Enoxaparin / Q000627:therapeutic use*; D005165:Factor V / Q000235:genetics; D005260:Female; D006801:Humans; D017354:Point Mutation; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; C095381:factor V Leiden; D005165:Factor V
Résistance à la protéine C activée et grossesse: thromboprophylaxie par les héparines de bas poids moléculaire.